Poster Session : PS 0941 ; Liver : One-Year Effi cacy of Tenofovir Treatment in Patients with Nucleo(t)ide-Naive Chronic Hepatitis B

Background: Tenofovir disoproxil fumarate (TDF) is a potent antiviral agent in treatment- naive chronic hepatitis B (CHB) patients. The aim of this study was to investigateone-year effi cacy of TDF in treatment-naive CHB patients. Methods: A total of 68 patients were enrolled in this study between DEC 2012 and AUG 2013. They received TDF 300 mg/d monotherapy for at least 6 months. All patients were assessed for virological response (HBV DNA<116 copies/mL) and biochemical response (ALT<40 IU/mL). Results: Mean age, baseline serum ALT level and serum HBV DNA level were 50.9 years (range, 25-82), 138 IU/L (range, 8-908) and 7.2 log10copies/ml (range, 3.5- 9.0), respectively. Forty nine patients were male (72.1%) and 46 (67.6%) were HBeAg positive at baseline. The mean duration of treatment was 14.4 months (range, 8-20). The rates of virologic response were 20.6% (14/68), 51.5% (35/68), and 72.9% (35/48) at month 3, 6, and 12, respectively. One patient did not respond to the drug at all despite good compliance. The rates of biochemical response were 54.4% (37/68), 69.1% (47/68), and 63.3% (31/49) at month 3, 6, and 12, respectively. Among 46 HBeAg positive patients, 4 (8.7%) and 2 (4.3%) patients achieved HBeAg loss and seroconversion, respectively. Low HBV DNA level at baseline was the most important predictive factor for virological response at year 1. The levels of phosphorus, creatinine, and GFR had no difference during the study period. Conclusions: TDF showed excellent virologic and biochemical response in the patients with CHB in real world study.